A rapidly emerging clinical application of positron emission tomography (PET) is the detection of tumor tissue at whole-body studies performed with the glucose analogue 2-[fluorine-18]fluoro-2-deoxy-dglucose (FDG). High rates of recurrence after partial hepatic resection in patients with colorectal cancer liver metastases indicate that current presurgical imaging strategies are failing to show extrahepatic tumor deposits. Although FDG PET cannot match the anatomic resolution of conventional imaging techniques in the liver and the lungs, it is particularly useful for identification and characterization of extrahepatic disease. FDG PET can show foci of metastatic disease that may not be apparent at conventional anatomic imaging and can aid in the characterization of indeterminate soft-tissue masses. Several sources of benign and physiologic increased activity at FDG PET emphasize the need for careful correlation with findings of other imaging studies and clinical findings. FDG PET can improve the selection of patients for partial hepatic resection and thereby reduce the morbidity and mortality associated with inappropriate surgery. 
Introduction
Functional metabolic imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) is emerging as a useful tool in the management of colorectal cancer (1) (2) (3) (4) (5) (6) . Findings of a meta-analysis showed that the technique has an overall sensitivity of 97% in the identification of colorectal cancer metastases throughout the whole body and that findings at FDG PET promote changes in management in 29% of cases (7) .
Colorectal cancer is the most common metastatic cancer to occur in the liver, and partial hepatic resection is now established as the optimal treatment for surgically resectable disease (8 -10) . However, improved survival rates are restricted to those patients from whom all metastases can be removed: Foci of disease at extrahepatic sites (not identified preoperatively) are responsible for relapse in approximately 50% of patients who have undergone this major surgical procedure (11, 12) . It is hoped that the application of FDG PET will lead to improved selection of patients for partial hepatic resection by optimizing the detection of extrahepatic tumor foci throughout the body. One recent series has shown improved survival rates among patients who underwent FDG PET prior to partial hepatic resection (13) .
The purpose of this article is to demonstrate the utility of FDG PET in the evaluation of liver metastases from colorectal cancer in patients who are being considered for partial hepatic resection and to emphasize the scope and limitations of the technique for the detection of extrahepatic tumor deposits.
Partial Hepatic Resection for Liver Metastases from Colorectal Cancer
In Western Europe and the United States, the incidence of colorectal cancer is approximately 400,000 new cases per year (10, 14, 15) . In up to 30% of patients, metastases localized to the liver will develop (16) . If the liver metastases are left untreated, patients have a dismal prognosis, with 5-year survival estimated at 3% or less, and the results of treatment with systemic chemotherapy or radiation therapy are poor (10) .
However, some of these patients will have resectable disease, and surgical treatment with partial hepatic resection offers the potential for cure. Approximately 25% of all colorectal cancer patients in whom liver metastases develop are potential candidates for surgical cure, making "resectable hepatic metastases. . .an oncologic problem of magnitude comparable to esophageal cancer, brain tumors, or thyroid cancer" (15) . Over the past few years, surgical management has become more aggressive, and recent studies have shown 5-year survival rates of 25%-44% among patients who underwent partial hepatic resection (8, 9) .
Consequently, this treatment has become standard for resectable disease but is a major therapeutic undertaking, with an operative mortality of 2%-7% (12) . The basic principle of partial hepatic resection is to remove all anatomically resectable liver lesions, leaving sufficient diseasefree liver tissue to allow normal hepatic function.
Candidates for partial hepatic resection should have anatomically resectable liver lesions and be free of extrahepatic disease. The role of preoperative imaging in patient selection is to identify this "small, but important, subgroup who may benefit from surgery and. . .to prevent unnecessary radical surgery. . .in those likely to gain only a shortterm benefit" (16) .
Although partial hepatic resection is the best available therapeutic option for such patients, the limited improvement in survival with surgery reflects high rates of tumor recurrence. Unidentified sites of extrahepatic disease are an important cause of clinical relapse: Extrahepatic sites are involved in up to 50% of patients who have recurrence after surgery (11, 12) . Also, a significant proportion of patients is found to have extrahepatic metastases at surgery (17, 18) ; the unnecessary laparotomy in these patients contributes significantly to morbidity and must be considered a failure of diagnostic imaging. Surgeons rely on preoperative imaging for patient selection, but current imaging strategies may fail to show small extrahepatic tumor foci. There is substantial scope for improvement in the preoperative detection of extrahepatic tumor deposits to prevent unnecessary surgery (7).
Principles of FDG PET
FDG PET provides a functional metabolic map of glucose uptake in the whole body. The glucose analogue FDG is labeled with the cyclotron-produced, positron-emitting radioisotope fluorine-18. The resulting radiopharmaceutical F-18 FDG is a substrate for glucose transport proteins in cell membranes and accumulates intracellularly.
Increased metabolic activity in malignant tissue is accompanied by increased glucose uptake relative to that of surrounding normal tissue. This focal increase in glucose uptake can be identified with FDG PET, which allows identification of malignant tumor foci. However, focal increased FDG uptake is nonspecific and may occur in any condition associated with increased tissue metab-olism, such as acute or chronic inflammatory processes. By forming images based on functional, rather than anatomic, information, FDG PET has the potential to show tumor foci at an early stage, before any structural abnormality becomes apparent. For instance, normal-sized lymph nodes that are infiltrated by tumor tissue may be identified in this way (19) . Similarly, the presence or absence of recurrent tumor tissue in postoperative scar tissue may be inferred by the degree of FDG uptake shown at FDG PET.
Use of FDG PET to Detect Colorectal Cancer Metastases
At most centers, computed tomography (CT) remains the principal imaging modality for the assessment of extrahepatic disease in patients with liver metastases from colorectal cancer who are being considered for partial hepatic resection. FDG PET has the potential to show increased metabolic activity in areas where the presence or absence of tumor tissue cannot be accurately assessed with conventional structural parameters (nonenlarged lymph nodes, low-volume peritoneal disease, postoperative sites). It may also raise suspicion of disease at sites that may have been overlooked or underestimated on the basis of CT findings.
Findings of a meta-analysis quote a "weighted average" sensitivity and specificity of 95% and 77%, respectively, for identification of colorectal cancer tumor deposits with whole-body FDG PET (7) . The same meta-analysis showed estimates of sensitivity and specificity of greater than 90% for identification of colorectal cancer liver metastases and of locoregional recurrence at sites of previous colonic resection. However, as the authors point out, published estimates of FDG PET performance in this context should be interpreted with some caution. In the absence of a perfect-criterion standard against which to compare the performance of FDG PET, and without exhaustive follow-up investigation in patients with apparently negative findings at FDG PET, it is impossible to accurately define test characteristics. In particular, the tendency to underestimate the false-negative rates may result in inappropriately high estimates of test sensitivity. Similarly, difficulties with verification of true-negative rates mean that test specificity is difficult to quantify accurately.
A few studies provide carefully verified data for FDG PET performance at specific anatomic sites and indicate that the sensitivity and specificity of FDG PET may be lower than some studies suggest. The sensitivity and specificity for identification of primary colorectal cancer lesions appear to be 95% and 43%, respectively (3), while for identification of pelvic colorectal cancer recurrence, the figures are estimated at 91% and 100%, respectively (20) . The specificity of 100% in the latter study (20) should probably be interpreted cautiously in view of several false-positive findings of pelvic recurrence in other studies (2, 3) . In two studies, FDG PET allowed identification of peritoneal tumor deposits in four of nine patients (sensitivity, 44%) (5, 6) . Histologic analysis of lymph nodes taken at surgery for primary colorectal cancer lesions suggests that the sensitivity of FDG PET for identification of involved lymph nodes may be only 29% (specificity, 96%) (3). Another factor indicating that sensitivity for identification of involved lymph nodes may be poorer than previously estimated is that modern molecular biology techniques can show tumor tissue in apparently uninvolved lymph nodes. In one study, these lymph node micrometastases were identified in 14 of 26 (54%) lymph node samples that were negative for colorectal cancer involvement at conventional histologic examination, and their presence was shown to be associated with reduced survival (21) .
The sensitivity of FDG PET for identification of mucinous-type colorectal cancer metastases is lower than that for the more common nonmucinous-type tumor (22) . As one might expect, the nondetectability of mucinous-type tumors has been shown to be associated with relative abundance of mucin and with tumor hypocellularity (23) .
Overall, compared with conventional anatomic imaging techniques, FDG PET has been shown to help in the identification of unexpected foci of tumor tissue in 46 of 229 patients (20%) in four studies (1, 2, 4, 6) . In candidates for partial hepatic resection (1, 4, 6) , findings at FDG PET are reported to have influenced management in 30 of 111 patients (27%).
In this article, we briefly describe our technique for FDG PET and show its use in patients who are potential candidates for partial hepatic resection. While findings at FDG PET of the liver are illustrated, most emphasis is placed on the evaluation of extrahepatic disease sites, which is where the real strength of FDG PET has been shown to lie. Cases of abdominal, pelvic, pulmonary, and mediastinal metastatic disease are presented alongside examples of physiologic and benign increased FDG uptake at sites that may mimic malignant disease. The importance of correlating FDG uptake with clinical findings and results of conventional, anatomic imaging studies is highlighted.
FDG PET Technique Image Acquisition
Our technique for FDG PET has been previously described in this journal (24), and we present an abbreviated summary here. Most patients are requested to fast for at least 6 hours prior to scanning. Patients with diabetes mellitus are allowed a normal therapeutic and dietary regimen at breakfast and then undergo fasting for 4 hours prior to injection of FDG. An intravenous dose of 5 mCi (185 MBq) of FDG is administered, and scanning is performed after a 45-minute delay for FDG uptake. Immediately before image acquisition, patients are encouraged to empty their bladders to reduce artifact from urinary FDG activity.
Images are acquired with an ECAT ART tomograph (Siemens/CTI, Knoxville, Tenn). This machine is a partial-ring bismuth germanate-crystal scanner that we use in three-dimensional mode (no septa) during whole-body imaging. Although the sensitivity (in terms of counts per minute per millicurie) is equivalent to that of more modern full-ring scanners, our images may appear noisier because of scatter. For these whole-body studies (pelvis to base of skull), emission data are acquired at four to six overlapping bed positions (8 minutes per position, 15-cm field of view, 6-cm overlap). We do not use attenuation correction for these examinations. The application of attenuation correction to whole-body PET is controversial (25) . In one lung cancer phantom study, attenuation correction was found to have no influence on lesion detectability (26) , while another study showed that attenuation correction may impair lesion detectability in patients with metastatic breast cancer (27) . Image reconstruction is performed with filtered back projection. In some instances, we apply an iterative reconstruction algorithm (ordered subset expectation maximization [OSEM], two iterations, eight subsets) to reduce the influence of artifacts that arise from filtered back projection (eg, when excessive artifact arises from intense bladder activity).
Image Interpretation
The data are viewed at a computer workstation (Sun Microsystems, Mountain View, Calif) that presents simultaneous reprojection images in three orthogonal planes (axial, coronal, and sagittal) and allows the reader to adjust image window and level settings to suit the particular study. The viewer may scroll through these displays and can also review a maximum pixel-weighted volumetric representation of the whole-body acquisition from all angles. We believe that this interactive approach is superior to reading from film. FDG PET images are interpreted alongside all other relevant imaging studies available at the time of referral; they include CT images of the chest, abdomen, and pelvis. In this article, we present many of the FDG PET images together with relevant CT findings.
Results of Hepatic and Extrahepatic FDG PET Studies Liver
The normal liver, like the spleen, renal cortex, and bone marrow, is a site of diffuse, moderate FDG activity (28) . Metastases usually manifest as during CT with arterial portography shows that the large perfusion defect in segments 2 and 3 is due to extensive tumor involvement. Another, discrete metastatic deposit is evident in segment 4a (arrowhead).
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discrete foci of increased activity in the liver (Fig  1) , but larger lesions, some of which have necrotic centers, may appear as rings of increased activity (Fig 2) . Large metastases are generally readily identified, but some small lesions are not identifiable at FDG PET (Fig 3) ; occasionally even large metastases are not associated with focal increased FDG uptake (Fig 4) . In a lesion-by-lesion analysis of resected liver specimens, FDG PET demonstrated only 70% of liver metastases, and the sensitivity of FDG PET in the detection of metastases was confirmed to be related to lesion size (6).
In these patients, the determination of operability of liver metastases is dependent on anatomic factors, including the relationship of lesions to blood vessels. FDG PET cannot provide such information. Nevertheless, it may show lesions not clearly evident at conventional cross-sectional imaging and may therefore complement other modalities by prompting reappraisal or by instigating further, targeted studies. 
Abdomen and Pelvis
Although a false-positive finding of focal FDG uptake is unusual in patients with liver metastases from colorectal cancer (6), several physiologic and benign causes of focally increased activity must be distinguished from metastatic disease. Increased activity can be seen in all segments of normal bowel tissue; the mechanism underlying this phenomenon is unclear (28) . This normal finding can usually be identified by its pattern, which is often a linear "string of beads" appearance (Figs 5, 6 ). More limited bowel uptake, which forms discrete foci of increased activity, can be impossible to distinguish from tumor deposits, and correlation with findings of other imaging modalities is required. Such focal FDG uptake is often seen in the stomach (Fig 7) and at ileostomy and colostomy sites (Fig 8) . Since stomas may be sites of tumor recurrence, correlation with clinical findings, as well as findings of other imaging studies, should be sought.
Sites of inflammation and healing may be associated with increased FDG uptake. For example, increased uptake in laparotomy scars may occur (Fig 9) . Again, these sites have potential for tumor recurrence, and correlation with clinical and CT findings, as well as consideration of biopsy, should be performed to identify early wound recurrence. With conventional imaging techniques, it can be difficult to exclude the presence of tumor recurrence at sites of postoperative surgical scar formation, especially in the pelvis. Increased FDG uptake, associated with healing, may persist for several months (29) . However, when postoperative scar tissue is identified in these patients, normal or low levels of FDG uptake are reassuring, as they imply the absence of tumor recurrence (Fig 10) .
FDG undergoes urinary excretion, and consequently, high levels of activity can be seen throughout the urinary collecting system (29) . Like that in the bowel, such activity can usually be identified by its pattern (Fig 11) . Although retention of FDG activity in dependent upper pole calices could potentially mimic tumor (28), we have found that the focal intensity of the activity in this scenario is so high that confusion is unlikely.
Lymph nodes involved by tumor tissue may be identifiable on FDG PET images as discrete foci of increased uptake in nonenlarged lymph nodes (Fig 12) , as well as in more conspicuous, enlarged lymph nodes (Fig 13) . Conversely, the absence of increased uptake in an enlarged lymph node Figures 12, 13. (12) Increased FDG uptake in a nonenlarged celiac lymph node involved by tumor tissue in a 75-year-old man. (a) FDG PET images show a discrete focus of increased FDG uptake in the celiac region (arrowheads). Foci of increased FDG uptake in the liver correspond to liver metastases in segments 4a (long arrow) and 4b (short arrow). (b) Corresponding axial CT image shows a nonenlarged lymph node at this site (arrowhead). This lymph node was not apparent at a previous CT study and was found to be enlarged at a subsequent CT study. Although no biopsy was performed (the patient had metastatic disease at other sites), these imaging changes strongly suggest that the lymph node is involved by tumor tissue. implies the absence of tumor involvement (Fig  14) . An advantage of whole-body FDG PET is the ability to survey the entire torso: This ability allows depiction of tumor deposits in involved lymph nodes above and below the diaphragm in one examination (Fig 2) . However, involved lymph nodes are not always associated with increased FDG uptake. For example, findings of FDG PET examinations were false-negative for 10 of 14 node-positive patients who underwent surgery for colorectal cancer primary lesions (3).
Low-volume peritoneal and mesenteric metastases are often unidentifiable at conventional imaging. Foci of increased uptake on FDG PET images may facilitate the identification of small tumor deposits (Fig 15) , but very-low-volume peritoneal tumor "seeding" can be difficult to diagnose. In one study, FDG PET failed to show peritoneal lesions less than 1 cm in diameter in Corresponding axial CT image shows a small soft-tissue mass in the mesenteric fat (arrow). Serial CT studies showed this nodule to be enlarging. Although no biopsy was performed, these imaging changes strongly suggest that the nodule is a tumor deposit.
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three of 25 patients who underwent laparotomy in preparation for partial hepatic resection (6) . Even when low-volume peritoneal disease is associated with increased FDG uptake, such uptake is usually patchy and may be attributed to benign uptake in normal small bowel tissue (Fig 16) . In such instances, where there is increased FDG uptake with no structural correlate from other imaging studies, we support the suggestion that unexplained suspicious foci of increased uptake should be explored rigorously by means of biopsy, endoscopy, or laparoscopy (1, 6) . In the future, increasing experience with FDG PET findings may lead us beyond the limitations of current conventional imaging and allow confident noninvasive diagnosis of low-volume malignant disease in the abdomen.
Chest
Lung metastases and mediastinal lymph node involvement can be identified with FDG PET (Figs 2, 17) . However, detection of lung nodules Figure 16 . Increased FDG uptake associated with low-volume peritoneal tumor deposits in a 70-year-old man. (a) FDG PET images show a patchy, diffuse region of increased FDG uptake in the central part of the abdomen (arrowheads). After examination of the images at the workstation, it was believed that the pattern of increased FDG uptake was not typical for normal bowel activity. (b) Axial CT image obtained in the same patient does not demonstrate any corresponding soft-tissue abnormality, and the patchy increased FDG uptake was attributed to activity in the bowel. The patient underwent laparotomy in preparation for partial hepatic resection, but multiple, small (Ͻ1-cmdiameter), biopsy-proved peritoneal tumor deposits were found. In retrospect, it appears that the unusual distribution of FDG uptake at the FDG PET study was due to these peritoneal tumor deposits. Increasing experience with FDG PET may allow us to select patients with this suspicious appearance for laparoscopy prior to partial hepatic resection. is size dependent (30) , and small lung metastases may be overlooked (Fig 18) . While FDG PET cannot match the spatial resolution of CT in the chest, the presence of increased FDG uptake in identified lung nodules is a strong indicator of malignancy; occasionally, unexpected primary lung cancers may be identified (Fig 19) .
In patients with primary lung cancer, FDG PET is more accurate than CT in the evaluation of mediastinal lymph node status (19) ; however, proved nodal involvement with colorectal cancer may not be associated with increased FDG up- take (Fig 20) . This finding may reflect differences in the biologic activity of these tumor types. In addition, increased FDG uptake, most likely attributable to inflammation, may be seen in noninvolved lymph nodes (Fig 21) or in the chest wall (Fig 22) . Such phenomena emphasize the importance of correlating FDG PET findings with other imaging findings, clinical information, and sometimes biopsy results before a surgical decision can be made. Corresponding axial CT image shows calcification in a nonenlarged left hilar lymph node (arrow). Several smaller hilar lymph nodes were similarly calcified. Although no definitive diagnosis was made, the increased FDG activity was most likely due to chronic low-grade inflammation, as no lymph node enlargement was evident on serial follow-up radiographs.
Summary
High recurrence rates after surgery for colorectal cancer liver metastases indicate that there is substantial scope for improvement of current presurgical imaging strategies in patients who are potential candidates for partial hepatic resection. FDG PET is a useful adjunct to conventional anatomic imaging modalities and assists in the selection of patients appropriate for surgery. Although FDG PET cannot match the anatomic resolution of conventional imaging techniques in the liver and the lungs, it is particularly useful for identification and characterization of extrahepatic disease. More accurate detection of extrahepatic tumor deposits will help avoid inappropriate surgery, with its associated morbidity and mortality. The utility of FDG PET is optimized when findings are carefully correlated with conventional imaging and clinical findings. FDG PET images show increased FDG uptake in the right pectoral muscle group (arrowheads). This finding is attributable to inflammation. The patient reported that he had strained these muscles during vigorous snow shoveling on the evening prior to scanning. Similar increased FDG uptake is sometimes seen in the gluteal muscles of patients who have been ambulant during the period between FDG injection and PET.
